|
Roche
and Trimeris Will Provide 60 Days Free Access to Fuzeon for Qualified
Patients
In
a “Dear Doctor” letter, Roche and Trimeris today announced a program
that offers free access to enfuvirtide
(Fuzeon) for up to 60 days for patients who qualify.
The primary qualification is patient participation in an HIV drug
Expanded Access Program. Click on link below for complete details:
FUZEON® (enfuvirtide) Accelerated Simultaneous
Access Program (FUZEON ASAP)
09/13/04
|
